Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 52-Week Low – Should You Sell?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as $8.41 and last traded at $8.52, with a volume of 44,188 shares. The stock had previously closed at $8.56.

Analysts Set New Price Targets

SNDX has been the topic of a number of recent research reports. HC Wainwright dropped their price objective on shares of Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. JPMorgan Chase & Co. dropped their target price on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Mizuho set a $43.00 price target on Syndax Pharmaceuticals in a report on Tuesday, November 3rd. Weiss Ratings raised Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, November 3rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $35.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $41.40.

Read Our Latest Stock Report on SNDX

Syndax Pharmaceuticals Price Performance

The stock has a 50-day moving average price of $14.22 and a two-hundred day moving average price of $19.44. The company has a current ratio of 4.69, a quick ratio of 4.37 and a debt-to-equity ratio of 38.95. The stock has a market cap of $785.96 million, a price-to-earnings ratio of -3.70 and a beta of 0.48.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). The company had revenue of $83.30 million during the quarter, compared to analysts’ expectations of $81.38 million. Syndax Pharmaceuticals had a negative return on equity of 804.38% and a negative net margin of 72.32%. The company’s quarterly revenue was up 81.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.70) EPS. As a group, equities research analysts forecast that Syndax Pharmaceuticals, Inc. will post -2.09 EPS for the current year.

Insider Buying and Selling

In other news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total value of $113,680.00. Following the sale, the director directly owned 239,763 shares of the company’s stock, valued at $3,407,032.23. This represents a 3.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.80% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

A number of hedge funds have recently modified their holdings of SNDX. Allworth Financial LP purchased a new position in Syndax Pharmaceuticals in the second quarter valued at $26,000. Sterling Capital Management LLC boosted its stake in shares of Syndax Pharmaceuticals by 846.6% during the 3rd quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock worth $56,000 after acquiring an additional 2,650 shares in the last quarter. Nykredit A S acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter valued at about $72,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter valued at about $73,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Syndax Pharmaceuticals in the 3rd quarter valued at about $86,000.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.

Further Reading

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.